HR-positive, HER2-negative Advanced Breast Cancer Clinical Trials

8 clinical trials for HR-positive, HER2-negative Advanced Breast Cancer across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors — RECRUITING · PHASE1
• Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer — RECRUITING · PHASE2
• Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study — RECRUITING
• A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy — RECRUITING · NA
• A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA) — NOT_YET_RECRUITING · PHASE2
• A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer — COMPLETED · PHASE2
• Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure — OTHER · PHASE1

Refine this search